ATTORNEY DOCKET NO. 47259-5001-00 US

Application No.: NEW

Page 3

IN THE CLAIMS:

Please amend the claims as follows:

Claim 1 (Original): A polypeptide cleavage method characterized in that arginine or lysine is at the P1 position of a desired cleavage site in a polypeptide, an amino acid other than aspartic acid, glutamic acid or proline is at the P1' position, a single basic amino acid or two or three consecutive basic amino acids are situated at any site in the amino acid sequence from the P10 position to the P3 position or from the P3' position to the P5' position (with the proviso that a single basic amino acid is not situated at the P6 or P4 position), and OmpT protease is used to cleave the desired cleavage site in said polypeptide.

Claim 2 (Original): A method for producing a target peptide characterized by obtaining a target peptide from a fusion protein, the cleavage site of the fusion protein being a desired cleavage site comprising a protecting peptide whose C-terminus is arginine or lysine, fused via the desired cleavage site with a target peptide whose N-terminus is an amino acid other than aspartic acid, glutamic acid or proline, wherein a single basic amino acid or two or three consecutive basic amino acids are situated at any site in the amino acid sequence from the P10 position to the P3 position or from the P3' position to the P5' position (with the proviso that in the case of a single basic amino acid, it is not situated at the P6 or P4 position), host cells are transformed with an expression plasmid having a gene coding for the fusion protein wherein said cleavage site is a cleavage site which is cleavable by OmpT protease, and said gene is expressed in said cells and is cleaved by said protease at said cleavage site.

Claim 3 (Currently amended): The method of claim 1 [[or 2]] wherein, if a site which is

not desired to be cleaved by OmpT protease is present in the polypeptide or the fusion protein,

cleavage at said site is inhibited by situating an acidic amino acid at the P3 position of said site.

Claim 4 (Currently amended): The method of claim 1 any one of claims 1 to 3, which

comprises situating two or three consecutive basic amino acids between the P10 and P3 positions

of the desired cleavage site in the polypeptide or fusion protein.

Claim 5 (Original): The method of claim 4, which comprises situating three consecutive

basic amino acids between the P5 and P3 positions of the desired cleavage site in the polypeptide

or fusion protein.

Claim 6 (Currently amended): The method of claim 1 any one of claims 1 to 5, wherein

the basic amino acids are arginine and/or lysine.

Claim 7 (Original): The method of 6, wherein the basic amino acids are arginine.

Claim 8 (Original): A polypeptide cleavage method wherein OmpT protease is used for

cleavage at a desired cleavage site in the polypeptide, or a method for producing a target peptide

which comprises cleavage at a desired cleavage site in a fusion protein, the method being

characterized in that, if a site which is not desired to be cleaved by OmpT protease is present in

said polypeptide or said fusion protein, cleavage at said site is inhibited by situating an acidic

amino acid at the P3 position of said site.

DC\560762\1

Claim 9 (Currently amended): The method of <u>claim 8</u> any one of claims 3 to 8, wherein the acidic amino acid is aspartic acid.

Claim 10 (Currently amended): The method of <u>claim 1</u> any one of claims 1 to 9, wherein the amino acid sequence from the P5 to P1 positions of the desired cleavage site in the polypeptide or fusion protein is Arg-Arg-Ala-Arg.

Claim 11 (Currently amended): The method of <u>claim 1</u> any one of claims 1 to 9, wherein the amino acid sequence from the P7 to P1 positions of the desired cleavage site in the polypeptide or fusion protein is Asp-Ala-Arg-Arg-Arg-Ala-Arg.

Claim 12 (Original): A polypeptide cleavage method characterized by cleaving a desired cleavage site of a polypeptide using an OmpT protease 97th amino acid variant wherein the 97th amino acid from the N-terminus of the OmpT protease is alanine, leucine, phenylalanine, methionine, serine, threonine, cysteine, asparagine, glutamine, glutamic acid or histidine.

Claim 13 (Original): A polypeptide cleavage method characterized in that, when the P1 position of the desired cleavage site in the polypeptide is arginine or lysine and the P1' position is an amino acid other than arginine or lysine, the desired cleavage site of said polypeptide is cleaved using an OmpT protease 97th amino acid variant wherein the 97th amino acid from the N-terminus of the OmpT protease is alanine, leucine, phenylalanine, methionine, serine, threonine, cysteine, asparagine, glutamine, glutamic acid or histidine.

ATTORNEY DOCKET NO. 47259-5001-00 US

Application No.: NEW

Page 6

Claim 14 (Original): A polypeptide cleavage method characterized in that the P1

position of the desired cleavage site in the polypeptide is arginine or lysine, the P1' position is an

amino acid other than arginine or lysine, a single basic amino acid or two or three consecutive

basic amino acids are situated at any site in the amino acid sequence from the P10 position to the

P3 position or from the P3' position to the P5' position, and the desired cleavage site of said

polypeptide is cleaved using an OmpT protease 97th amino acid variant wherein the 97th amino

acid from the N-terminus of the OmpT protease is alanine, leucine, phenylalanine, methionine,

serine, threonine, cysteine, asparagine, glutamine, glutamic acid or histidine.

Claim 15 (Original): A method for producing a target peptide, characterized by

transforming host cells with an expression plasmid having a gene coding for a fusion protein

comprising a target peptide fused with a protecting peptide via a desired cleavage site that can be

cleaved by an OmpT protease 97th amino acid variant wherein the 97th amino acid from the N-

terminus of the OmpT protease is alanine, leucine, phenylalanine, methionine, serine, threonine,

cysteine, asparagine, glutamine, glutamic acid or histidine, expressing said gene in said cells, and

obtaining the target peptide from the fusion protein by cleavage with said protease at said

cleavage site.

Claim 16 (Original): A method for producing a target peptide, characterized by

transforming host cells with an expression plasmid having a gene coding for a fusion protein

comprising a protecting peptide whose C-terminus is arginine or lysine fused with a target

peptide whose N-terminus is an amino acid other than arginine or lysine, via a desired cleavage

site that can be cleaved by an OmpT protease 97th amino acid variant wherein the 97th amino

DC\560762\1

acid from the N-terminus of the OmpT protease is alanine, leucine, phenylalanine, methionine, serine, threonine, cysteine, asparagine, glutamine, glutamic acid or histidine, expressing said gene in said cells, and obtaining the target peptide from the fusion protein by cleavage with said protease at said cleavage site.

Claim 17 (Original): A method for producing a target peptide, characterized by transforming host cells with an expression plasmid having a gene coding for a fusion protein wherein a single basic amino acid or two or three consecutive basic amino acids are situated at any site in the amino acid sequence from the P10 position to the P3 position or from the P3' position to the P5' position at a desired cleavage site of a fusion protein comprising a protecting peptide whose C-terminus is arginine or lysine fused with a target peptide whose N-terminus is an amino acid other than arginine or lysine, via the cleavage site, and said desired cleavage site is a cleavage site that can be cleaved by an OmpT protease 97th amino acid variant wherein the 97th amino acid from the N-terminus of the OmpT protease is alanine, leucine, phenylalanine, methionine, serine, threonine, cysteine, asparagine, glutamine, glutamic acid or histidine, expressing said gene in said cells, and obtaining the target peptide from the fusion protein by cleavage with said protease at said cleavage site.

Claim 18 (Currently amended): The method of claim 12 any one of claims 12 to 17 wherein, if a site which is not desired to be cleaved by the OmpT protease 97th amino acid variant is present in the polypeptide or fusion protein, cleavage at said site is inhibited by situating an acidic amino acid at the P3 position of said site.

Claim 19 (Currently amended): The method of claim 12 any one of claims 12 to 18, which comprises situating two or three consecutive basic amino acids between the P10 and P3 positions of the desired cleavage site in the polypeptide or fusion protein.

Claim 20 (Original): The method of claim 19, which comprises situating three consecutive basic amino acids between the P5 and P3 positions of the desired cleavage site in the polypeptide or fusion protein.

Claim 21 (Currently amended): The method of claim 14 any one of claims 14 or 17 to 20, wherein the basic amino acids are arginine and/or lysine.

Claim 22 (Original): The method of claim 21, wherein the basic amino acids are arginine.

Claim 23 (Original): A polypeptide cleavage method wherein an OmpT protease 97th amino acid variant is used for cleavage at a desired cleavage site in the polypeptide, or a method for producing a target peptide which comprises cleavage at a desired cleavage site in a fusion protein, the method being characterized in that, if a site which is not desired to be cleaved by the OmpT protease 97th amino acid variant is present in said polypeptide or said fusion protein, cleavage at said site is inhibited by situating an acidic amino acid at the P3 position of said site.

Claim 24 (Currently amended): The method of <u>claim 18</u> any one of claims 18 to 23, wherein the acidic amino acid is aspartic acid.

Claim 25 (Currently amended): The method of claim 12 any one of claims 12 to 24, wherein the amino acid sequence from the P5 to P1 positions of the desired cleavage site in the polypeptide or fusion protein is Arg-Arg-Ala-Arg.

Claim 26 (Currently amended): The method of <u>claim 12</u> any one of claims 12 to 24, wherein the amino acid sequence from the P7 to P1 positions of the desired cleavage site in the polypeptide or fusion protein is Asp-Ala-Arg-Arg-Arg-Arg-Ala-Arg.

Claim 27 (Currently amended): The method of <u>claim 12</u> any one of claims 12 to 26, wherein the 97th amino acid from the N-terminus of the OmpT protease is leucine, methionine or histidine.

Claim 28 (Currently amended): The method of <u>claim 12</u> any one of claims 12 to 26, wherein the P1' position of the desired cleavage site of the polypeptide or fusion protein or the N-terminus of the target peptide is serine or alanine, and the 97th amino acid of the OmpT protease 97th amino acid variant used is leucine.

Claim 29 (Currently amended): The method of claim 12 any one of claims 12 to 26, wherein the P1' position of the desired cleavage site of the polypeptide or fusion protein or the N-terminus of the target peptide is phenylalanine, alanine, serine, cysteine or tyrosine, and the 97th amino acid of the OmpT protease 97th amino acid variant used is methionine.

Claim 30 (Currently amended): The method of claim 12 any one of claims 12 to 26, wherein the P1' position of the desired cleavage site of the polypeptide or fusion protein or the N-terminus of the target peptide is alanine, valine, isoleucine, methionine, serine, threonine, cysteine or asparagine, and the 97th amino acid of the OmpT protease 97th amino acid variant used is histidine.

Claim 31 (Currently amended): The method of <u>claim 2</u> any one of <u>claims 2</u> to 11 and 15 to 30, wherein the target peptide is a peptide composed of between 22 and 45 amino acid residues.

Claim 32 (Original): The method of claim 31, wherein the target peptide is adrenocorticotropic hormone (1-24), motilin or calcitonin precursor.

Claim 33 (Currently amended): The method of <u>claim 2</u> any one of claims 2 to 11 and 15 to 32, wherein the host cells are *E. coli*.

Claim 34 (Currently amended): The method of <u>claim 1</u> any one of claims 1 to 33, which comprises using as the cleaving protease bacterial cells expressing a gene coding for OmpT protease or an OmpT protease 97th amino acid variant wherein the 97th amino acid from the N-terminus of OmpT protease is alanine, leucine, phenylalanine, methionine, serine, threonine, cysteine, asparagine, glutamine, glutamic acid or histidine.

ATTORNEY DOCKET NO. 47259-5001-00 US

Application No.: NEW

Page 11

Claim 35 (Currently amended): The method of claim 1 any one of claims 1 to 33, which

comprises co-expressing a gene coding for OmpT protease or an OmpT protease 97th amino acid

variant wherein the 97th amino acid from the N-terminus of OmpT protease is alanine, leucine,

phenylalanine, methionine, serine, threonine, cysteine, asparagine, glutamine, glutamic acid or

histidine, and a gene coding for a polypeptide or fusion protein whose cleavage by said protease

is desired.